Posted by Michael Wonder on 20 Jul 2017
Teva’s Cinqaero to challenge Nucala after clearing NICE
20 July 2017 - NICE has recommended Teva’s treatment for severe asthma Cinqaero, allowing it to challenge GSK’s rival Nucala.
Both drugs target eosinophils, the immune cells which trigger severe asthma symptoms in some patients.
Teva gained the prized recommendation after confidential discount persuaded NICE to change its mind from an earlier ‘no’ ruling.
